This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Can a WIZARD Change It All?

Sorin V. Pislaru, MD, PhD; Frans Van de Werf, MD, PhD

JAMA. 2003;290:1515-1516.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The possible association between Chlamydia pneumoniae and atherosclerosis was first reported in 1988 by Saikku et al¹ who noted that antichlamydial antibodies were present more often among patients with acute myocardial infarction (MI) than among matched controls. Since then, several other serological studies have yielded conflicting results about this association, possibly due to lack of uniformity in methods used (ie, different classes of antibodies tested, different methods, different cutoff points) and by the high prevalence of C pneumoniae exposure in the population. On the other hand, data from basic laboratory studies have strongly suggested a possible role of C pneumoniae in the etiology of atherosclerosis. Cells involved in atherogenesis (vascular endothelial cells, smooth muscle cells, macrophages, and platelets) have been found to be infected by C pneumoniae.² In mouse and rabbit models, C pneumoniae has been detected in . . . [Full Text of this Article]

Author Affiliations: Department of Cardiology, Mayo Clinic and Foundation, Rochester, Minn (Dr Pislaru) and Department of Cardiology, Gasthuisberg University Hospital and University of Leuven, Leuven, Belgium (Dr Van de Werf).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study: A Randomized Controlled Trial
Christopher M. O'Connor, Michael W. Dunne, Marc A. Pfeffer, Joseph B. Muhlestein, Louis Yao, Sandeep Gupta, Rebecca J. Benner, Marian R. Fisher, and Thomas D. Cook
JAMA. 2003;290(11):1459-1466.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research
de Kruif et al.
Cardiovasc Res 2005;65:317-327.
ABSTRACT | FULL TEXT  

Antibiotics and Coronary Heart Disease
Nieto
JAMA 2004;291 :302-303.
FULL TEXT  

Short-Term Antibiotic Therapy Not Effective for Secondary Prevention of CAD
Journal Watch Cardiology 2003;2003:2-2.
FULL TEXT